172 completed, 8 unknown, 7 recruiting, 6 terminated. 66 Phase 3, 57 Phase 2, 34 Phase 4, 23 Not applicable, 14 Phase 1.
Follow Seasonal Allergic Rhinitis: new trials by email Literature Review of Seasonal Allergic Rhinitis trials Research Report on Seasonal Allergic Rhinitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets, Rupatifen Fumarate Capsules Placebo - Seasonal Allergic Rhinitis | Phase 3 | Recruiting | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | 550 | 2026-08-18 | 2026-09-09 |
| A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 220 | 2026-08-11 | 2026-10-22 |
| Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis TQH2722 injection - Seasonal Allergic Rhinitis | Phase 2 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 300 | 2026-03-19 | 2026-03-27 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis AK139, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Not yet recruiting | Akeso | 111 | 2026-03-02 | 2026-02-27 |
| A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis PG-011 nasal spray 0.6%(twice daily), Placebo - Seasonal Allergic Rhinitis, SAR | Phase 3 | Not yet recruiting | Prime Gene Therapeutics Co., Ltd. | 600 | 2025-09-15 | 2025-08-28 |
| Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study Observational - Allergic Asthma, Thunderstorm Asthma | Not applicable | Recruiting | University of Melbourne | 530 | 2025-08-27 | 2026-05-06 |
| A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 108 | 2025-08-06 | 2026-08-27 |
| Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis TQC2938 injection, TQC2938 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 136 | 2025-07-31 | 2026-02-10 |
| Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis Placebo, MG-K10 Humanized Monoclonal Antibody Injection - Seasonal Allergic Rhinitis | Phase 2 / Phase 3 | Recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 160 | 2025-03-20 | 2025-04-18 |
| A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Placebo (twice daily) - Seasonal Allergic Rhinitis | Phase 2 | Completed | Prime Gene Therapeutics Co., Ltd. | 179 | 2025-03-12 | 2026-09-09 |
| Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis TQH2722 injection, TQH2722 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 169 | 2025-03-10 | 2025-08-12 |
| Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults JT002 Nasal spray, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai JunTop Biosciences Co., LTD | 370 | 2025-02-24 | 2025-06-11 |
| Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis LP-003, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Longbio Pharma | 546 | 2024-08-01 | 2025-12-26 |
| Study of CM310 in Subjects With Seasonal Allergic Rhinitis CM310 - Seasonal Allergic Rhinitis | Phase 2 | Unknown | Keymed Biosciences Co.Ltd | 100 | 2024-03-30 | 2023-12-14 |
| Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis Interleukin-4 receptor responders, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Recruiting | Beijing Tongren Hospital | 120 | 2024-03-18 | 2025-09-25 |
| Azelastine Allergen Chamber - Onset of Action Study Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray - Seasonal Allergic Rhinitis | Phase 2 | Completed | MEDA Pharma GmbH & Co. KG | 84 | 2023-10-30 | 2024-03-20 |
| A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis Mometasone furoate as a nasal spray - Seasonal Allergic Rhinitis | Phase 3 | Completed | Zheng Liu ENT | 640 | 2023-08-25 | 2026-10-05 |
| Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult LP-003 dose 1, LP-003 dose 2, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Longbio Pharma | 180 | 2023-07-06 | 2025-12-15 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Mometasone + Azelastine, Mometasone Furoate, Azelastine Hydrochloride - Seasonal Allergic Rhinitis | Phase 1 | Terminated | Sandoz | 38 | 2023-06-08 | 2023-09-28 |
| Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray Azelastine Hydrochloride/ Fluticasone propionate nasal spray, 'DYMISTA' NASAL SPRAY - Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 56 | 2023-03-24 | 2023-12-28 |
Showing 20 of 198. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (198) · Rhinitis, Allergic (18) · Hypersensitivity (16) · Rhinitis (13) · Rhinitis, Allergic, Perennial (7) · Sneezing (7) · Asthma (6) · Rhinorrhea (6) · Nasal Obstruction (4) · Conjunctivitis, Allergic (2) · Pruritus (2) · Conjunctivitis (1) · Dermatitis, Atopic (1) · Disorders of Excessive Somnolence (1) · Inflammation (1)
Hypersensitivity, Immediate (198) · Immune System Diseases (198) · Nose Diseases (198) · Otorhinolaryngologic Diseases (198) · Respiratory Hypersensitivity (198) · Respiratory Tract Diseases (197) · Rhinitis (185) · Hypersensitivity (182) · Rhinitis, Allergic (180) · Infections (15) · Respiratory Tract Infections (14) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (8) · Signs and Symptoms, Respiratory (8) · Bronchial Diseases (6)
azelastine (22) · Cetirizine (14) · Mometasone Furoate (14) · Fluticasone (13) · desloratadine (13) · fexofenadine (9) · montelukast (8) · bilastine (7) · Loratadine (6) · Nasal Sprays (5) · Beclomethasone (4) · Budesonide (4) · MP29-02 (4) · fluticasone furoate (4) · Pseudoephedrine (3)
Organon and Co (25) · Meda Pharmaceuticals (10) · GlaxoSmithKline (7) · Fraunhofer-Institute of Toxicology and Experimental Medicine (6) · University of Chicago (6) · Faes Farma, S.A. (5) · AstraZeneca (4) · Bausch & Lomb Incorporated (4) · Beijing Tongren Hospital (4) · Alcon Research (3) · Allergy Therapeutics (3) · Apotex Inc. (3) · Bayer (3) · Capnia, Inc. (3) · Circassia Limited (3)
United States (63) · China (20) · Canada (17) · Germany (14) · Austria (8) · Poland (5) · United Kingdom (5) · Japan (3) · Russia (3) · Bulgaria (2) · Denmark (2) · Hungary (2) · Italy (2) · Netherlands (2) · Australia (1)
Lewis M Fredane, MD (6) · Luo Zhang (4) · Robert M Naclerio, MD (3) · Tim McNamara, PharmD (3) · Anish Bhatnagar, MD (2) · Deepen Patel, MD (2) · Luo Zhang, Professor (2) · Norbert Krug, MD (2)
PMID 28392807, PMID 12086367, PMID 12100048, PMID 15049402, PMID 16913264, PMID 17021320, PMID 19127072, PMID 19132976, PMID 19428097, PMID 19438584, PMID 19441605, PMID 19449366, PMID 19504468, PMID 19647862, PMID 19788025, PMID 19943178, PMID 20350147, PMID 20377116, PMID 20434199, PMID 20674829, PMID 20819468, PMID 21067660, PMID 21130386, PMID 21261661, PMID 21262099, PMID 21477426, PMID 22287431, PMID 22370531, PMID 23026180, PMID 23181790, PMID 23299716, PMID 23406601, PMID 23420231, PMID 23562197, PMID 23636036, PMID 23786282, PMID 23806461, PMID 23815103, PMID 24125150, PMID 24261946, PMID 24708643, PMID 24814759, PMID 24983742, PMID 25624132, PMID 25705889, PMID 26141263, PMID 26560899, PMID 26897304, PMID 27613466, PMID 28270216
2004 (1), 2019 (1), 2023 (1)